$JAZZ
Jazz Pharmaceuticals PLC

2024 Q3 Form 10-Q Financial Statement

#000123252424000068 Filed on August 01, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $1.055B $1.024B
YoY Change 8.52% 6.95%
Cost Of Revenue $111.6M $109.9M
YoY Change 9.21% 12.68%
Gross Profit $943.4M $913.9M
YoY Change 8.43% 6.3%
Gross Profit Margin 89.42% 89.27%
Selling, General & Admin $325.8M $338.5M
YoY Change 5.66% -0.68%
% of Gross Profit 34.53% 37.04%
Research & Development $199.9M $220.7M
YoY Change -14.71% 5.49%
% of Gross Profit 21.19% 24.15%
Depreciation & Amortization $165.2M $155.2M
YoY Change 1.62% -2.73%
% of Gross Profit 17.52% 16.98%
Operating Expenses $525.7M $559.3M
YoY Change -3.14% 1.67%
Operating Profit $260.2M $199.4M
YoY Change 50.94% 26.52%
Interest Expense -$58.70M -$62.02M
YoY Change -17.9% -15.58%
% of Operating Profit -22.56% -31.1%
Other Income/Expense, Net
YoY Change
Pretax Income $200.8M $137.9M
YoY Change 101.78% 68.65%
Income Tax -$14.50M -$30.70M
% Of Pretax Income -7.22% -22.26%
Net Earnings $215.1M $168.6M
YoY Change 46.48% 61.4%
Net Earnings / Revenue 20.38% 16.46%
Basic Earnings Per Share $3.50 $2.68
Diluted Earnings Per Share $3.42 $2.49
COMMON SHARES
Basic Shares Outstanding 61.75M shares 63.04M shares
Diluted Shares Outstanding 63.17M shares 69.63M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.618B $1.981B
YoY Change 65.08% 45.4%
Cash & Equivalents $2.218B $1.356B
Short-Term Investments $400.0M $625.0M
Other Short-Term Assets $354.2M $325.9M
YoY Change 14.11% 19.6%
Inventory $539.3M $542.6M
Prepaid Expenses $155.1M $134.4M
Receivables $723.6M $698.0M
Other Receivables $0.00 $140.1M
Total Short-Term Assets $4.390B $3.682B
YoY Change 35.27% 22.32%
LONG-TERM ASSETS
Property, Plant & Equipment $253.6M $242.4M
YoY Change -11.95% -18.73%
Goodwill $1.805B $1.736B
YoY Change 5.82% -0.39%
Intangibles $5.144B $5.079B
YoY Change -5.05% -10.98%
Long-Term Investments
YoY Change
Other Assets $75.23M $71.43M
YoY Change -1.12% 8.26%
Total Long-Term Assets $7.865B $7.680B
YoY Change -1.17% -6.91%
TOTAL ASSETS
Total Short-Term Assets $4.390B $3.682B
Total Long-Term Assets $7.865B $7.680B
Total Assets $12.26B $11.36B
YoY Change 9.39% 0.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $85.43M $97.10M
YoY Change -22.23% -1.35%
Accrued Expenses $858.6M $801.0M
YoY Change 11.51% 7.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $31.00M $605.8M
YoY Change -94.87% 1854.19%
Total Short-Term Liabilities $1.030B $1.556B
YoY Change -34.54% 64.61%
LONG-TERM LIABILITIES
Long-Term Debt $6.081B $5.101B
YoY Change 18.98% -10.3%
Other Long-Term Liabilities $111.0M $99.42M
YoY Change -12.95% -21.52%
Total Long-Term Liabilities $6.192B $5.200B
YoY Change 18.2% -10.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.030B $1.556B
Total Long-Term Liabilities $6.192B $5.200B
Total Liabilities $7.222B $6.756B
YoY Change 6.02% -0.03%
SHAREHOLDERS EQUITY
Retained Earnings $936.2M $871.2M
YoY Change 5.87% 7.31%
Common Stock $3.838B $3.779B
YoY Change 5.43% 5.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.171B $3.763B
YoY Change
Total Liabilities & Shareholders Equity $12.26B $11.36B
YoY Change 9.39% 0.9%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $215.1M $168.6M
YoY Change 46.48% 61.4%
Depreciation, Depletion And Amortization $165.2M $155.2M
YoY Change 1.62% -2.73%
Cash From Operating Activities $398.7M $331.4M
YoY Change 29.8% 11.65%
INVESTING ACTIVITIES
Capital Expenditures $10.79M $7.091M
YoY Change 150.88% 23.56%
Acquisitions
YoY Change
Other Investing Activities $224.9M -$250.0M
YoY Change -232.28% 212.5%
Cash From Investing Activities $214.1M -$257.1M
YoY Change -222.83% 199.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 246.4M -161.1M
YoY Change -414.32% 66.64%
NET CHANGE
Cash From Operating Activities 398.7M 331.4M
Cash From Investing Activities 214.1M -257.1M
Cash From Financing Activities 246.4M -161.1M
Net Change In Cash 859.3M -86.82M
YoY Change 1476.63% -175.92%
FREE CASH FLOW
Cash From Operating Activities $398.7M $331.4M
Capital Expenditures $10.79M $7.091M
Free Cash Flow $388.0M $324.3M
YoY Change 28.08% 11.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
145279000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
69420000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
3335041000 usd
us-gaap Net Income Loss
NetIncomeLoss
153950000 usd
CY2024Q2 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2024Q2 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2023Q4 us-gaap Derivative Asset Statement Of Financial Position Extensible Enumeration
DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent
CY2023Q4 us-gaap Derivative Liability Statement Of Financial Position Extensible Enumeration
DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
3085734000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21228000 usd
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
43266000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
56646000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2003000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8863000 usd
CY2023Q2 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
95594000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
113407000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
104438000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3525675000 usd
us-gaap Net Income Loss
NetIncomeLoss
173858000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
310953000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
301848000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
118095000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
117785000 usd
jazz Inventory Step Up Value Adjustment
InventoryStepUpValueAdjustment
62186000 usd
jazz Inventory Step Up Value Adjustment
InventoryStepUpValueAdjustment
88272000 usd
us-gaap Depreciation
Depreciation
15465000 usd
us-gaap Depreciation
Depreciation
15089000 usd
jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
13186000 usd
jazz Provision For Losses On Accounts Receivable And Inventory
ProvisionForLossesOnAccountsReceivableAndInventory
5550000 usd
jazz Noncash Interest Expense
NoncashInterestExpense
11200000 usd
jazz Noncash Interest Expense
NoncashInterestExpense
10193000 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
10000000 usd
us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
1000000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-141568000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-145395000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-15520000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-48156000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-277000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-42439000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17591000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7082000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-34872000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3392000 usd
jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-7199000 usd
jazz Increase Decrease In Operating Lease Assets
IncreaseDecreaseInOperatingLeaseAssets
-11578000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
5699000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
12908000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4148000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7462000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5404000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-89808000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
18030000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
45937000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-459000 usd
jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-6909000 usd
jazz Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-11950000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1841000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
19300000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
598581000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
617473000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
705000000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
80000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13995000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9561000 usd
jazz Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination
PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination
10000000 usd
jazz Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination
PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination
1000000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
200000000 usd
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-528995000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-90561000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
161428000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
95595000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
52143000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
47454000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
15500000 usd
us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
15500000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
11434000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
32094000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-217637000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-126455000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-2457000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
365000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-150508000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
400822000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1506310000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
881482000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1355802000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1282304000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</span></div>We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding.<div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier.</span></div>
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1980802000 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1980802000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1355802000 usd
CY2024Q2 us-gaap Investments
Investments
625000000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1626310000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1626310000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1506310000 usd
CY2023Q4 us-gaap Investments
Investments
120000000 usd
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
25400000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
48600000 usd
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
14700000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
25300000 usd
CY2024Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
4300000 usd
CY2023Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
4300000 usd
us-gaap Cash Flow Hedge Gain Loss To Be Reclassified Within Twelve Months
CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
3700000 usd
CY2024Q2 us-gaap Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement
DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
6715000 usd
CY2023Q4 us-gaap Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement
DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement
21819000 usd
CY2024Q2 us-gaap Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement
DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
1579000 usd
CY2023Q4 us-gaap Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement
DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement
4091000 usd
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
20805000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
25595000 usd
CY2024Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
340299000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
431732000 usd
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
181451000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
139712000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
542555000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
597039000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
1753130000 usd
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-17199000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
1735931000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7753643000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2674181000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5079462000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
7800209000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2382170000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5418039000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
310564000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
621128000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
621128000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
621128000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
619796000 usd
CY2024Q2 jazz Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
2285718000 usd
CY2024Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5079462000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
315544000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
302997000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
146263000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
133351000 usd
CY2024Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
169281000 usd
CY2023Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
169646000 usd
CY2024Q2 jazz Deferred Tax Intercompany Profit Current
DeferredTaxIntercompanyProfitCurrent
185740000 usd
CY2023Q4 jazz Deferred Tax Intercompany Profit Current
DeferredTaxIntercompanyProfitCurrent
171507000 usd
CY2024Q2 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
140111000 usd
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
149302000 usd
CY2024Q2 us-gaap Other Assets Current
OtherAssetsCurrent
325851000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
320809000 usd
CY2024Q2 jazz Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
380679000 usd
CY2023Q4 jazz Accrued Rebates And Other Sales Deductions Current
AccruedRebatesAndOtherSalesDeductionsCurrent
325711000 usd
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
85943000 usd
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
121209000 usd
CY2024Q2 jazz Accrued Clinical Trial Liability Current
AccruedClinicalTrialLiabilityCurrent
39043000 usd
CY2023Q4 jazz Accrued Clinical Trial Liability Current
AccruedClinicalTrialLiabilityCurrent
44757000 usd
CY2024Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
37914000 usd
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
30706000 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
36316000 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
36443000 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
30543000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
19538000 usd
CY2024Q2 jazz Sales Return Reserve Current
SalesReturnReserveCurrent
23331000 usd
CY2023Q4 jazz Sales Return Reserve Current
SalesReturnReserveCurrent
20435000 usd
CY2024Q2 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
21329000 usd
CY2023Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
14743000 usd
CY2024Q2 jazz Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
17147000 usd
CY2023Q4 jazz Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
19447000 usd
CY2024Q2 jazz Accrued Inventory Related Liabilities Current
AccruedInventoryRelatedLiabilitiesCurrent
13775000 usd
CY2023Q4 jazz Accrued Inventory Related Liabilities Current
AccruedInventoryRelatedLiabilitiesCurrent
13977000 usd
CY2024Q2 jazz Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
12554000 usd
CY2023Q4 jazz Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
10158000 usd
CY2024Q2 jazz Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
9862000 usd
CY2023Q4 jazz Accrued Construction In Progress Current
AccruedConstructionInProgressCurrent
5141000 usd
CY2024Q2 jazz Accrued Facilities Expenses Current
AccruedFacilitiesExpensesCurrent
3657000 usd
CY2023Q4 jazz Accrued Facilities Expenses Current
AccruedFacilitiesExpensesCurrent
55455000 usd
CY2024Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1579000 usd
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
681000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
87321000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
75513000 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
800993000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
793914000 usd
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
5706781000 usd
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
5712942000 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
605798000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
604954000 usd
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5100983000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
5107988000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
590500000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
31000000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1031000000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
31000000 usd
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
2598500000 usd
CY2024Q2 jazz Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
1500000000 usd
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
5782000000 usd
CY2021Q2 jazz Infringed Patents Suit Other Party Counterclaim Number Of Patents Requested To Be Delisted
InfringedPatentsSuitOtherPartyCounterclaimNumberOfPatentsRequestedToBeDelisted
1 patent
us-gaap Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
-43380000 usd
us-gaap Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
2700000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-46080000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
168568000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
104438000 usd
us-gaap Net Income Loss
NetIncomeLoss
153950000 usd
us-gaap Net Income Loss
NetIncomeLoss
173858000 usd
CY2024Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
4878000 usd
CY2023Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
7076000 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
9733000 usd
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
14039000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
173446000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
111514000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
163683000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
187897000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62882000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63991000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
62710000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
63744000 shares
CY2024Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
6418000 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
9044000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
6418000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
9044000 shares
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
325000 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
505000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
556000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
869000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69625000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73540000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69684000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73657000 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.68
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.73
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.49
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.52
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.35
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.55
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1023825000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
957317000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1925808000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1850129000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1023825000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
957317000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1925808000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1850129000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
56654000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
61433000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
118095000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
117785000 usd
CY2024Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
9629000 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
11122000 usd
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
13028000 usd
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
19741000 usd
CY2024Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
47025000 usd
CY2023Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
50311000 usd
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
105067000 usd
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
98044000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-30700000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-19000000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24300000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-39600000 usd
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001232524-24-000068-index-headers.html Edgar Link pending
0001232524-24-000068-index.html Edgar Link pending
0001232524-24-000068.txt Edgar Link pending
0001232524-24-000068-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
jazz-20240630.htm Edgar Link pending
jazz-20240630.xsd Edgar Link pending
jazzq22024ex102.htm Edgar Link pending
jazzq22024ex311.htm Edgar Link pending
jazzq22024ex312.htm Edgar Link pending
jazzq22024ex321.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
jazz-20240630_cal.xml Edgar Link unprocessable
jazz-20240630_def.xml Edgar Link unprocessable
jazz-20240630_pre.xml Edgar Link unprocessable
jazz-20240630_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
jazz-20240630_lab.xml Edgar Link unprocessable